Clinical trial
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320…
NCT00170937 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00170937 |
|---|---|
| Title | A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome |
| Official title | A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan and Hydrochlorothiazide Combined and Alone, in Patients With Metabolic Syndrome |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION |
| Intervention type | Drug |
| Interventions | valsartan plus hydrochlorothiazide |
| Enrollment | 507 |
| Start date | Nov 1, 2004 |
| Primary completion | Mar 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 18, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: